KRAS and neoplasm: Kaplan Meier median OS estimates of patients with relapsed disease are shown, based on tumor sidedness and receipt of bevacizumab (Figure 1, panel A and B) and EGFRI therapy in KRAS wild type (wt) tumors (Figure 1, panel C and D).